BioNumerik Pharmaceuticals Inc. is topping off 2003 with more than $35 million in cash, thanks to a $29 million private placement with existing investors. (BioWorld Today)

Novacea Inc. in-licensed a Phase I cancer drug known as AQ4N from KuDOS Pharmaceuticals Inc., gaining North American rights in exchange for undisclosed development milestone payments and royalties. (BioWorld Today)